Results 61 to 70 of about 29,283 (148)

Polypharmacy and Potential Drug–Drug Interactions in Patients With Atrial Fibrillation

Journal of Clinical Pharmacy and Therapeutics, Volume 2025, Issue 1, 2025.
What is Known and Objective: The use of multiple medications, or polypharmacy, is associated with an elevated risk of potential drug–drug interactions (pDDIs), consequently heightening the probability of adverse drug reactions. Currently, there is a dearth of data regarding pDDIs in Chinese patients with atrial fibrillation (AF) within real‐world ...
Ying Bai, Jianqi Wang, Guangyao Li, Zhen Zhou, Nicholas B. Norgard   +4 more
wiley   +1 more source

Pharmacokinetic interactions of pioglitazone [PDF]

, 2007
Pioglitazone is a thiazolidinedione compound used in the treatment of type 2 diabetes. It has been reported to be metabolised by multiple cytochrome P450 (CYP) enzymes, including CYP2C8, CYP2C9 and CYP3A4 in vitro.
Jaakkola, Tiina
core  

TRAF3 Epigenetic Regulation Is Associated With Vascular Recurrence in Patients With Ischemic Stroke [PDF]

, 2016
Clopidogrel is one of the most used antiplatelet drugs in patients with cardiovascular disease. However, 16% to 50% of patients have a high on-clopidogrel platelet reactivity and an increased risk of ischemic events. The pathogenesis of high on-treatment
Carrera, Caty, Cullell, Natalia, Fernandez-Cadenas, Israel, Fontana, Pierre, Gallego-Fabrega, Cristina, Krupinski, Jerzy, Martí-Fàbregas, Joan, Montaner, Joan, Muiño, Elena, Pera, Joanna, Pezzini, Alessandro, Reny, Jean-Luc, Segura, Tomás, Serrano-Heras, Gemma, Slowik, Agnieszka   +14 more
core   +2 more sources

Clinical applications of pharmacogenomics [PDF]

, 2017
Indexación: Scopus.Pharmacogenomics is an emergent field aimed at tailoring pharmacological therapy. Genetic polymorphisms can modify the expression and function of enzymes and proteins involved in drug metabolism, affecting absorption, distribution ...
Cayún, J.P., Escalante, P., Gallegos, B., Lares-Asseff, I., Meneses, F., Miranda, C., Quiñones, L., Roco, Á., Varela, N., Zaruma-Torres, F.   +9 more
core   +1 more source

Cannabidiol Increases Psychotropic Effects and Plasma Concentrations of Δ9‐Tetrahydrocannabinol Without Improving Its Analgesic Properties

Clinical Pharmacology &Therapeutics, Volume 116, Issue 5, Page 1289-1303, November 2024.
Cannabidiol (CBD), the main non‐intoxicating compound in cannabis, has been hypothesized to reduce the adverse effects of Δ9‐tetrahydrocannabinol (THC), the main psychoactive and analgesic component of cannabis. This clinical trial investigated the hypothesis that CBD counteracts the adverse effects of THC and thereby potentially improves the ...
Andriy A. Gorbenko, Jules A.A.C. Heuberger, Linda E. Klumpers, Marieke L. de Kam, Pamela K. Strugala, Saco J. de Visser, Geert J. Groeneveld   +6 more
wiley   +1 more source

Translational high-dimensional drug Interaction discovery and validation using health record databases and pharmacokinetics models [PDF]

, 2017
Polypharmacy increases the risk of drug-drug interactions (DDI's). Combining epidemiological studies with pharmacokinetic modeling, we detected and evaluated high-dimensional DDI's among thirty frequent drugs.
Chiang, Chien-Wei, Li, Lang, Ning, Xia, Quinney, Sara K., Shen, Li, Wang, Lei, Wang, Xueying, Zhang, Pengyue, Zhang, Shijun   +8 more
core   +1 more source

Quadruple therapies show a higher eradication rate compared to standard triple therapy for Helicobacter pylori infection within the LEGACy consortium. A multicenter observational study in European and Latin American countries

United European Gastroenterology Journal, Volume 12, Issue 9, Page 1190-1199, November 2024.
Abstract Introduction Gastric cancer (GC) is one of the most lethal malignancies worldwide. Helicobacter pylori is the primary cause of GC; therefore, its eradication reduces the risk of developing this neoplasia. There is extensive evidence regarding quadruple therapy with relevance to the European population.
Patricio Medel‐Jara, Diego Reyes Placencia, Eduardo Fuentes‐López, Oscar Corsi, Gonzalo Latorre, Rosario Antón, Elena Jiménez, Ana Miralles‐Marco, Carmelo Caballero, Hugo Boggino, Daniel Cantero, Rita Barros, João Santos‐Antunes, Marc Díez, Luis A. Quiñones, Erick Riquelme, Antonio Rollán, Leslie C. Cerpa, Ivania Valdés, Olga P. Nyssen, Leticia Moreira, Javier P. Gisbert, M. Constanza Camargo, Nayeli Ortiz‐Olvera, Alberto M. Leon‐Takahashi, Erika Ruiz‐Garcia, Edith A. Fernández‐Figueroa, Marcelo Garrido, Gareth I. Owen, Andrés Cervantes, Tania Fleitas, Arnoldo Riquelme   +31 more
wiley   +1 more source

Optimized Cocktail Phenotyping Study Protocol Using Physiological Based Pharmacokinetic Modeling and In silico Assessment of Metabolic Drug–Drug Interactions Involving Modafinil [PDF]

, 2016
In vivo cocktail pathway phenotyping (ICPP) is routinely used to assess the metabolic drug–drug interaction (mDDI) potential of new drug candidates (NDC) during drug development.
Andrew Rowland, Angela Rowland, Arduino A. Mangoni, Ashley Hopkins, Michael J. Sorich   +4 more
core   +1 more source

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C9 and HLA-B Genotype and Phenytoin Dosing [PDF]

, 2014
Phenytoin is a widely used antiepileptic drug with a narrow therapeutic index and large inter-patient variability partly due to genetic variations in CYP2C9.
Callaghan, J. Thomas, Caudle, Kelly E., Klein, Teri E., Lee, Ming Ta Michael, Mintzer, Scott E., Rettie, Allan E., Smith, Lisa H., Whirl-Carrillo, Michelle   +7 more
core   +3 more sources

The cytochrome P450 isoenzyme and some new opportunities for the prediction of negative drug interaction in vivo

Drug Design, Development and Therapy, 2018
Dmitrij A Sychev,1 Ghulam Md Ashraf,2 Andrey A Svistunov,3 Maksim L Maksimov,4 Vadim V Tarasov,3 Vladimir N Chubarev,3 Vitalij A Otdelenov,1 Natal’ja P Denisenko,1 George E Barreto,5,6 Gjumrakch Aliev7–9 1Russian Medical Academy of ...
Sychev DA, Ashraf GM, Svistunov AA, Maksimov ML, Tarasov VV, Chubarev VN, Otdelenov VA, Denisenko NP, Barreto GE, Aliev G   +9 more
doaj